Abstract
Raised in Switzerland's capital Bern, Matthias Egger had the importance of education instilled early by his architect father, whereas his humanitarian passion came from his mother who worked with the International Committee of the Red Cross. “But my first interest in medicine came from a family tragedy”, Egger tells The Lancet Infectious Diseases. “My brother died suddenly, when I was just 10 years old, probably from complications of influenza.” Drug susceptibility testing and mortality in patients treated for tuberculosis in high-burden countries: a multicentre cohort studyInaccurate drug susceptibility testing by comparison with a reference standard leads to under-treatment of drug-resistant tuberculosis and increased mortality. Rapid molecular drug susceptibility test of first-line and second-line drugs at diagnosis is required to improve outcomes in patients with MDR tuberculosis and pre-XDR or XDR tuberculosis. Full-Text PDF
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
